Table 2.
Factors associated with hepatocellular carcinoma (HCC) development.
| At SVR24 | ||||||
| Univariate | Multivariate | |||||
| HR | 95%CI | p value | HR | 95%CI | p value | |
| Age (every 10 years) | 1.90 | 1.20–2.99 | 0.006 | |||
| Sex (male) | 1.31 | 0.59–2.93 | 0.5 | |||
| Albumin (g/dL) | 0.22 | 0.09–0.56 | 0.001 | |||
| Bilirubin (mg/dL) | 2.34 | 0.69–7.98 | 0.2 | |||
| AST (every 30 IU/L) | 4.40 | 1.69–11.4 | 0.002 | |||
| ALT (every 30 IU/L) | 3.42 | 1.40–8.35 | 0.007 | |||
| Platelet counts (×104/μL) | 0.87 | 0.80–0.94 | <0.001 | |||
| WFA±M2BP ≥ 1.85 (COI) | 9.43 | 3.91–22.7 | <0.001 | 5.29 | 2.07–13.0 | <0.001 |
| AFP ≥ 6.0 (ng/mL) | 8.17 | 3.63–18.4 | <0.001 | 4.27 | 1.84–9.94 | <0.001 |
| Presence of LR3/4 nodules | 15.4 | 6.06–39.2 | <0.001 | 8.49 | 3.29–21.9 | <0.001 |
| 1 Year after SVR24 | ||||||
| Univariate | Multivariate | |||||
| HR | 95%CI | p value | HR | 95%CI | p value | |
| Age (every 10 years) | 2.40 | 0.91–6.31 | 0.08 | |||
| Sex (male) | 0.64 | 0.12–3.30 | 0.6 | |||
| Albumin (g/dL) | 0.17 | 0.04–0.65 | 0.01 | |||
| Bilirubin (mg/dL) | 2.12 | 0.27–16.6 | 0.5 | |||
| AST (every 30 IU/L) | 2.52 | 0.46–13.7 | 0.3 | |||
| ALT (every 30 IU/L) | 1.18 | 0.11–12.1 | 0.9 | |||
| Platelet counts (×104/μL) | 0.81 | 0.69–0.94 | 0.005 | |||
| WFA±M2BP ≥ 1.85 (COI) | 35.3 | 4.25–293 | <0.001 | 23.5 | 2.68–205 | 0.004 |
| AFP ≥ 6.0 (ng/mL) | 1.23 | 0.15–10.2 | 0.9 | |||
| Presence of LR3/4 nodules | 60.1 | 13.2–273 | <0.001 | 24.1 | 5.02–116 | <0.001 |
HCC, hepatocellular carcinoma; SVR, sustained virological response; HR, hazard ratio; CI, confidence interval, AST, aspartate aminotransferase; ALT, alanine aminotransferase; WFA±M2BP, Wisteria floribunda agglutinin-positive mac-2 binding protein; COI, cut off index; AFP, alpha-fetoprotein; LR, liver imaging reporting and data system; LR3, intermediate probability of HCC; LR4, probably of HCC.